Back to top

Bio-Reference Labs

Read MoreHide Full Article
Bio-Reference Labs (BRLI) recently beat earnings estimates once again. Shares are up roughly 10% since being featured as a Zacks Rank Buy in December.

Company Description

Bio-Reference Laboratories, Inc provides clinical laboratory testing services such as blood and urine analysis in the New York metropolitan area. The company was founded in 1981 and has a market cap of $536 million.

Another Surprise

On Mar 4 Bio-Reference reported first-quarter results that included a 31% jump in revenue. The growth came on over patient growth as well as revenue per patient.

Earnings per shares came in at 29 cents, 6 cents ahead of expectations. Bio-Referance has now topped estimates 7 times in a row.

Analysts React

Bio-Reference analysts raised their estimates following the news. The Zacks Consensus Estimate for fiscal 2010 is up 4 cents to $1.81. Forecasts for 2011 are averaging $2.13, up a penny.

If projections are met, earnings growth rates will be 20% for this year and another 18% next year.

Read the December Feature Here

Last Week's Aggressive Growth Zacks Rank Buy Stocks

Lennar Corp. (LEN) reported optimistic results in the face of an uncertain housing market. Shares and estimates are surging. Read Full Article.

Continental Airlines (CAL) estimates are rising at a break-neck pace and shares just set a new multi-year high. Read Full Article.

Schawk Inc. (SGK) just beat expectations and shares are soaring yet, thanks to rapidly rising estimates, remain a great value with plenty of growth. Read Full Article.

Cenveo, Inc (CVO) recently beat Wall Street's expectations, sending shares to a new 52-week high. Thanks to upward estimate revisions, shares are still a good value. Read Full Article.

Bill Wilton is the Growth Stock Strategist for He is also the Editor in charge of the market-beating Zacks Growth Trader service

Normally $25 each - click below to receive one report FREE:

More from Zacks Aggressive Growth

You May Like